Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of “Moderate Buy” by Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has received an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $12.17.

A number of brokerages have recently weighed in on IRWD. Wells Fargo & Company lowered their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 16th. Craig Hallum lowered their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, Leerink Partners began coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They set a “market perform” rating and a $5.00 target price on the stock.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the transaction, the insider now owns 284,661 shares in the company, valued at approximately $1,215,502.47. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently modified their holdings of IRWD. Charles Schwab Investment Management Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 4.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,288,653 shares of the biotechnology company’s stock valued at $14,742,000 after purchasing an additional 57,859 shares in the last quarter. Norges Bank acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $9,321,000. Aigen Investment Management LP boosted its holdings in shares of Ironwood Pharmaceuticals by 58.3% in the 4th quarter. Aigen Investment Management LP now owns 21,270 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 7,833 shares in the last quarter. Armistice Capital LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 64.9% in the 4th quarter. Armistice Capital LLC now owns 5,700,000 shares of the biotechnology company’s stock valued at $65,208,000 after purchasing an additional 2,244,000 shares in the last quarter. Finally, Old West Investment Management LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 1.4% in the 4th quarter. Old West Investment Management LLC now owns 56,921 shares of the biotechnology company’s stock valued at $651,000 after purchasing an additional 761 shares in the last quarter.

Ironwood Pharmaceuticals Stock Down 1.0 %

NASDAQ:IRWD opened at $4.02 on Monday. The stock’s 50 day moving average price is $5.12 and its two-hundred day moving average price is $6.50. The firm has a market capitalization of $629.25 million, a price-to-earnings ratio of -0.61 and a beta of 0.49. Ironwood Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $15.70.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.